147 related articles for article (PubMed ID: 1337430)
1. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
Kiura K; Ohnoshi T; Ueoka H; Takigawa N; Tabata M; Segawa Y; Shibayama T; Kimura I
Anticancer Drug Des; 1992 Dec; 7(6):463-70. PubMed ID: 1337430
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
[TBL] [Abstract][Full Text] [Related]
3. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].
Takigawa N; Ohnoshi T; Ueoka H; Yonei T; Kiura K; Tabata M; Kodani T; Kamei H; Segawa Y; Shibayama T
Gan To Kagaku Ryoho; 1993 May; 20(7):929-35. PubMed ID: 8387762
[TBL] [Abstract][Full Text] [Related]
4. An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line.
Kiura K; Watarai S; Ueoka H; Tabata M; Gemba K; Aoe K; Yamane H; Yasuda T; Harada M
Anticancer Res; 1998; 18(4C):2957-60. PubMed ID: 9713491
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance].
Kimura I; Ohnoshi T; Hiraki S; Miyamoto H
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):830-6. PubMed ID: 3032107
[TBL] [Abstract][Full Text] [Related]
7. The in vitro effects of lonidamine combined with cisplatin in human small cell lung cancer cell lines.
Ko D; Raaphorst GP; Feeley MM; Danjoux CE; Maroun JA; Evans WK
Anticancer Res; 1991; 11(1):235-9. PubMed ID: 1850216
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
Ikubo S; Takigawa N; Ueoka H; Kiura K; Tabata M; Shibayama T; Chikamori M; Aoe K; Matsushita A; Harada M
Anticancer Res; 1999; 19(5B):3985-8. PubMed ID: 10628341
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
10. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Kimura I
Acta Med Okayama; 1992 Aug; 46(4):249-56. PubMed ID: 1442149
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer].
Takigawa N; Ohnoshi T; Ueoka H; Horiguchi T; Kiura K; Tabata M; Segawa Y; Shibayama T; Genba K; Matsumura T
Gan To Kagaku Ryoho; 1993 Jul; 20(9):1221-6. PubMed ID: 8392827
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
Hong WS; Jung HY; Yang SK; Kim HR; Min YI
Anticancer Res; 1997; 17(5A):3613-6. PubMed ID: 9413212
[TBL] [Abstract][Full Text] [Related]
14. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
15. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
[TBL] [Abstract][Full Text] [Related]
16. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Moritaka T; Tabata M; Segawa Y; Shibayama T; Gemba K; Matsumura T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):473-7. PubMed ID: 8383949
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
Ning SC; Hahn GM
Cancer Res; 1990 Dec; 50(24):7867-70. PubMed ID: 2253227
[TBL] [Abstract][Full Text] [Related]
20. The effect of lonidamine alone and in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines.
Raaphorst GP; Ko D; Feeley MM; Danjoux CE; Maroun J; Evans WK
Anticancer Res; 1991; 11(1):41-7. PubMed ID: 2018379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]